ArticleThe Lancet. Respiratory medicine2021
Nebulised interferon beta-1a for patients with COVID-19.
Article in The Lancet. Respiratory medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Gene Expression Meta-Analysis Reveals Interferon-Induced Genes Associated With SARS Infection in Lungs.Frontiers in immunologyPooled it
- Article
- Quantum DFT studies on the drug delivery of favipiravir using pristine and functionalized chitosan nanoparticles.Scientific reports · 2023Article
- Secreted Protein Acidic and Rich in Cysteine (SPARC) to Manage Coronavirus Disease-2019 (COVID-19) Pandemic and the Post-COVID-19 Health Crisis.Medicines (Basel, Switzerland) · 2023Article
- Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19.Drug delivery and translational research · 2023Review
- A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19.Life (Basel, Switzerland) · 2022Review
- Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19.Biomedicines · 2022Review
- Immune system changes in those with hypertension when infected with SARS-CoV-2.Cellular immunology · 2022Review
- Mechanisms of Antiviral Immune Evasion of SARS-CoV-2.Journal of molecular biology · 2022Review
- Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L.Journal of medicinal chemistry · 2022Article
- Review
- The role of type I interferon in the treatment of COVID-19.Journal of medical virology · 2022Review
- Identification and Development of Therapeutics for COVID-19.mSystems · 2021Article
- The early interferon catches the SARS-CoV-2.The Journal of experimental medicine · 2021Article
- Coronavirus induces diabetic macrophage-mediated inflammation via SETDB2.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Potential drug development and therapeutic approaches for clinical intervention in COVID-19.Bioorganic chemistry · 2021Review
- Interferon β, an enhancer of the innate immune response against SARS-CoV-2 infection.Microbial pathogenesis · 2021Review
- Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model.PLoS pathogens · 2021Article
- Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein Using mRNA Display.ACS central science · 2021Article
- The 15-Months Clinical Experience of SARS-CoV-2: A Literature Review of Therapies and Adjuvants.Antioxidants (Basel, Switzerland) · 2021Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.